NOVELTY - A controlled-release preparation comprises diacetylene monomer, phospholipid, and anticancer drug at molar ratio of 0-100:0-100:1-5. The phospholipid includes phosphatidylcholine, phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, distearoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dipalmitoyl phosphatidic acid, dioleoylphosphatidylcholine, dioleoylphosphatidylethanolamine, or phosphatidylcholine.    USE - Controlled-release preparation used as polydiacetylene liposome anticancer drug (claimed).    ADVANTAGE - The controlled-release preparation has low toxicity, high stability, and controllability for releasing drug; and is high in sealing rate and carrying rate for anticancer drug, simple in process with mild reaction condition, good in repeatability and pollution-free.    DETAILED DESCRIPTION - A controlled-release preparation comprises diacetylene monomer, phospholipid, and anticancer drug at molar ratio of 0-100:0-100:1-5. The phospholipid is phosphatidylcholine, phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, distearoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dipalmitoyl phosphatidic acid, dioleoylphosphatidylcholine, dioleoylphosphatidylethanolamine, phosphatidylcholine, soybean phospholipid, natural cephalin, synthesized cephalin, and/or cardiolipin. The diacetylene monomer is of formula R-CC-CC-R'.    R=CH3, CH3(CH2)4, CH3(CH2)9, COOH, COOH(CH2)4, COOH(CH2)9, PO4(CH2)2N(CH3)3, PO4(CH2)2N(CH3)3(CH2)4, or PO4(CH2)2N(CH3)3(CH2)9; and    R'=(CH2)15CH3, (CH2)17CH3, or (CH2)19CH3.    An INDEPENDENT CLAIM is included for production of the controlled-release preparation, comprising:    (A) mixing diacetylene monomer, phospholipid and anticancer drug and dissolving the mixture with an organic solvent to obtain mixed solution A;    (B) arranging the solution A on a rotary evaporator, rotating and decompressing and evaporating to dry at 20-70 degrees C to obtain a lipid membrane;    (C) arranging the lipid membrane into a buffer solution with pH of 2-12, ultrasonically oscillating for 15-30 minutes at 20-70 degrees C and at ultrasonic power of 40-400 W till the lipid membrane is dissolved completely to obtain mixed solution B; and    (D) irradiating the mixed solution B for 10-60 minutes under UV light of 10-20 W to obtain the controlled-release preparation.